Seventure starts second microbiome-focussed fund

While Seventure’s first Health for Life Capital Fund (HCF I), which closed at €160m, was backed by Novartis and Danone, HCF II has additional backing by aUS-based global food ingredient provider besides cornerstone investors of HCF I. Seventure’s latest fund will keep its core focus on the microbiome, including platforms, drugs, nutritional solutions, diagnostics and biomarkers, as well as opportunistic investments in digital therapeutics, connected health, digital nutritional advice, personalised nutrition, precision medicine and food technologies

“We are proud to be trusted by prestigious industry champions as Danone, Novartis, our new US global food ingredient provider, Lesaffre, Bel, Unigrains etc. …Our industry partners display strong innovative oriented strategy. They are world leaders and pioneers in supporting innovative food and health concepts” commented Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, who led the fund raising.

Seventure launched HFL in 2014, anticipating the microbiome revolution in the health and nutrition sectors. According to Cremoux, “research and investment in the microbiome was at its infancy when we launched our first fund in 2014. Fast-forward to 2019 and, alongside digital health, precision medicine and personalized nutrition, the microbiome has exploded and is one of the hottest areas for healthcare and nutrition investment.” Seventure has invested in an innovative portfolio of twenty companies at the forefront of their fields, such as Enterome, Vedanta Biosciences, MaaT Pharma, Eligo Bioscience, LNC Therapeutics, TargEDys, A-Mansia Biotech, BiomX, Microbiotica, Anaeropharma, NeurIMM, Siolta Therapeutics, DayTwo, Zipongo, Mdoloris Medical Systems, MycoTechnology and others. It achieved its first transactional exit with the trade sale of Cambrooke in 2017.

HFL II will seek to invest in a similar number of companies, with a global focus, spanning Europe, North America, Israel, and opportunistically Asia. HFL II has already committed to its first two investments, Axial Biotherapeutics in the US and Galecto Biotech in Denmark.